Subscribe to this RSS feed

Vitiligo News

First positive observations from Clinuvel’s US vitiligo trial

21 Oct 2011
Read more...
In October 2011 early clinical observations from the company’s open label Phase II pilot trial (CUV102) of the novel drug SCENESSE® (afamelanotide) in patients with nonsegmental vitiligo (NSV) were presented at the European Academy of Dermatology and Venereology (EADV) meeting in Lisbon. You can read the full announcement here.

Clinuvel Blog Posts

Inside Clinuvel: Rare diseases day 2013 - rare disea...

Today, February 28, marks Rare Disease Day: an annual event to help highlight the effects of rare diseases on individuals, families and the...

Read More

Q&A: SCENESSE® successful in Phase IIa vitiligo...

We've just released the first results from our vitiligo program which you can view online here. Following their release, we expect a number...

Read More

Inside Clinuvel: Vitiligo and the “Michael Jackson...

I find vitiligo to be a fascinating, yet devastating disorder: almost overnight, patients see their skin colour erode and their identity...

Read More

Clinuvel Webcasts

What can vitiligo patients do? – Lee Thomas and Dr ...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

The future of vitiligo treatment – Lee Thomas and D...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Vitiligo trials of SCENESSE® – Lee Thomas and Dr Ph...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now